No information is available on the use of mavacamten during breastfeeding. Because it is 97 to 98% plasma protein bound, the amount of mavacamten in milk is likely to be very low. If a mother requires mavacamten, it is not a reason to discontinue breastfeeding. Until more data become available, mavacamten should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Mavacamten
CAS Registry Number
1642288-47-8
Drug Class
Breast Feeding
Lactation
Milk, Human
Cardiovascular Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
